The Protocol Review and Monitoring System (PRMS) for the NYUCI is responsible for evaluating the scientific merit of all cancer-related population-based, translational and clinical research studies that take place on the NYU Langone Medical Center campus and those of its strategic alliances. Once the clinical protocol documentation has been completed, the PRMS provides a forum for multi-level review, confirming the scientific merit and programmatic fit. After the NYU School of Medicine Institutional Review Board (IRB) approves the protocol, the PRMS monitors for scientific progress and performance. A central core of the PRMS is the Protocol Review and Monitoring Committee (PRMC). PRMC membership is drawn from the membership of the NYUCI based on expertise in the development and conduct of clinical trials, as well as leadership in key clinical positions. Physician members of the committee represent the different subspecialties providing care and participating in clinical research within the NYUCI. In addition, the PRMC includes bench scientists, biostatisticians, members of the administrative staff of the NYUCI, oncology nursing and the investigational pharmacy. PRMC approval is required for IRB submission and approval. PRMC review includes the underlying hypothesis, design, and the likelihood that the trial will lead to clinically meaningful results. The PRMC monitors accrual yearly and requires that investigators provide a formal plan to increase enrollment if accrual is <50% of projected target. The PRMC has the authority to close under-accruing trials. Investigator initiated studies are the highest priority for the NYUCI especially those involving novel agents based on laboratory results from NYUCI basic and/or translational scientists. The number of reviewed protocols has increases since the last review. In 2011, PRMC reviewed 126 protocols as compared to 94 in 2007.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-34
Application #
8765186
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
34
Fiscal Year
2014
Total Cost
$14,144
Indirect Cost
$5,799
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Kim, Sungheon G; Feng, Li; Grimm, Robert et al. (2016) Influence of temporal regularization and radial undersampling factor on compressed sensing reconstruction in dynamic contrast enhanced MRI of the breast. J Magn Reson Imaging 43:261-9
Zakhar, Joseph; Amrock, Stephen M; Weitzman, Michael (2016) Passive and Active Tobacco Exposure and Children's Lipid Profiles. Nicotine Tob Res 18:982-7
Pham, Alissa M; Santa Maria, Felicia Gilfoy; Lahiri, Tanaya et al. (2016) PKR Transduces MDA5-Dependent Signals for Type I IFN Induction. PLoS Pathog 12:e1005489
Pylayeva-Gupta, Yuliya; Das, Shipra; Handler, Jesse S et al. (2016) IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. Cancer Discov 6:247-55
Lau, Colleen M; Nish, Simone A; Yogev, Nir et al. (2016) Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses. J Exp Med 213:415-31
Vogelsang, Matjaz; Martinez, Carlos N; Rendleman, Justin et al. (2016) The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis. Clin Cancer Res 22:3268-80
Domènech-Estévez, Enric; Baloui, Hasna; Meng, Xiaosong et al. (2016) Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS. J Neurosci 36:4506-21
Abdu, Yusuff; Maniscalco, Chelsea; Heddleston, John M et al. (2016) Developmentally programmed germ cell remodelling by endodermal cell cannibalism. Nat Cell Biol 18:1302-1310
Reynaud, Olivier; Winters, Kerryanne Veronica; Hoang, Dung Minh et al. (2016) Pulsed and oscillating gradient MRI for assessment of cell size and extracellular space (POMACE) in mouse gliomas. NMR Biomed 29:1350-63
Sun, Xiaoqiang; Bao, Jiguang; Shao, Yongzhao (2016) Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. Sci Rep 6:22498

Showing the most recent 10 out of 878 publications